Prof.Dr. Mehmet Birhan Yılmaz Kardiyoloji Uzmanı
Prof.Dr. Mehmet Birhan Yılmaz

Merhaba, Sizlerle web sitem üzerinden tecrübelerimi paylaşmaktan büyük mutluluk duyacağım. Sağlık Dolu Günler Dilerim. Hello, I will be happy to share my experiences with you on my website. I wish you a healthy living


Doktora Sor
Prof.Dr. Mehmet Birhan Yılmaz

Eğitim Bilgileri

Mezun Oldugu Okul1985Cengiz Topel İlkokulu
Izmir
1988Torbalı Lisesi (Ortakokul kısmı)
Izmir
1991Adana Fen Lisesi
Adana
1998Hacettepe Üniversitesi
Tıp Fakültesi (İngilizce Tıp)
Ankara
2003Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Kardiyoloji Kliniği
Ankara

Eğitim Sertifikaları2010Fellow of ESC (FESC)

İş Deneyimi

İş Deneyimi2003-2005Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi Kardiyoloji Kliniği
2005-2011Cumhuriyet Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı, Sivas
2007-2007Harvard Tıp Fakültesi-Observer
2009-2010Lariboisiere Hospital, INSERM U 942, Paris Diderot University, Post-doc fellow

Mesleki Üyelikleri

  • Türk Kardiyoloji Derneği (TKD-TSC) [Certification: The Turkish Board on Cardiology of TSC], TKD Kalp Yetersizliği Çalışma Grubu Üyeliği, Working Group on Cardiovascular Imaging of TSC, Working Group on Arrhythmia of TSC, Working Group on Valvular Heart Disease of European Society of Cardiology (ESC), Working Group on Cardiovascular Pharmacology and Drug Therapy of ESC, Working Group on Acute Cardiac Care of ESC, Heart Failure Association of ESC, European Association for Cardiovascular Prevention and Rehabilitation, Fellow of ESC

Tıbbi Yayınlar

  • Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011 Nov;13(11):1244-52.
  • Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011 Apr;37(4):619-26.
  • Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikström BG, Jörgensen K, Filippatos G, Parissis JT, González MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F. Levosimendan: Molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2011 Jul 23. [Epub ahead of print]
  • Yılmaz MB, Zorlu A, Bektaşoğlu G, Yontar OC, Tandoğan I. The product of eGFR and hemoglobin may help predict mortality in systolic heart failure patients without severe anemia and renal failure. Turk Kardiyol Dern Ars. 2012 Jan;40(1):9-15
  • Yilmaz MB, Nikolaou M, Cohen Solal A. Tumour biomarkers in heart failure: is there a role for CA-125? Eur J Heart Fail. 2011 Jun;13(6):579-83. Epub 2011 Apr 26. Review.
  • Yilmaz MB, Zorlu A, Dogan OT, Karahan O, Tandogan I, Akkurt I. Role of CA-125 in identification of right ventricular failure in chronic obstructive pulmonary disease. Clin Cardiol. 2011 Apr;34(4):244-8.
  • Yilmaz MB, Laribi S, Mebazaa A. Managing beta-blockers in acute heart failure: when to start and when to stop? Curr Heart Fail Rep. 2010 Sep;7(3):110-5. Review.
  • Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol. 2011 May 19;149(1):80-2
  • Yilmaz MB, Yontar C, Erdem A, Karadas F, Yalta K, Turgut OO, Yilmaz A, Tandogan I. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009 Jan;24(1):16-21.
  • Yilmaz MB. Levosimendan and ventriculo-arterial coupling. Acta Anaesthesiol Scand. 2008 Mar;52(3):449
  • Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007 Dec;21(6):431-5
  • Yilmaz MB, Karadas F, Erdem A, Tandogan I. Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin. Int J Cardiol. 2008 Mar 28;125(1):104-6
  • Yilmaz MB, Refiker M, Guray Y, Guray U, Altay H, Demirkan B, Caldir V, Korkmaz S. Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life? Int J Clin Pract. 2007 Feb;61(2):225-30.
  • Yilmaz MB, Tufekcioglu O, Korkmaz S, Sabah I. Dynamic cardiomyoplasty: impact of effective pacing. Int J Cardiol. 2003 Sep;91(1):101-2
  • Zoghi M, Cavuşoğlu Y, Yilmaz MB, Nalbantgil S, Eren M, Mebazaa A. [Practical approach to acute heart failure with algorithms]. Anadolu Kardiyol Derg. 2009 Dec;9(6):436-46. Turkish.
  • Turgut O, Tandogan I, Yilmaz MB, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol. 2010 Nov 5;145(1):71
  • Salem R, Sibellas F, Socrates T, Arenja N, Yilmaz MB, Mueller C, Mebazaa A. Novelties in the early management of acute heart failure syndromes. Swiss Med Wkly. 2010 Jul 22;140:w13031. doi: 10.4414/smw.2010.13031. Review.
  • Refiker M, Yilmaz MB. Association of right heart with CA-125 levels in patients with heart failure. Int J Cardiol. 2010 Dec 3;145(3):521-2.
  • Ege MR, Yilmaz N, Yilmaz MB. High mortality among heart failure patients treated with antidepressants. Int J Cardiol. 2011 Jan 7;146(1):94.
  • Yilmaz MB, Mebazaa A. In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting. Crit Care. 2011 Aug 18;15(4):182.
  • Yılmaz MB, Cohen-Solal A, Mebazaa A. Very early management of acute heart failure syndromes. Turk Kardiyol Dern Ars. 2011 Jul;39(5):427-32. Review.
  • Zorlu A, Yilmaz MB, Yucel H, Bektasoglu G, Refiker Ege M, Tandogan I. Increased d-dimer levels predict cardiovascular mortality in patients with systolic heart failure. J Thromb Thrombolysis. 2012 May;33(4):322-8.
  • Zorlu A, Tandogan I, Yilmaz MB. CA-125, an omitted part of the heart. Heart Lung Circ. 2011 May;20(5):345
  • Ege MR, Yucel O, Zorlu A, Yilmaz MB. Letter to editor: clinical profile and predictors of in-hospital outcome in patients with heart failure. Int J Cardiol. 2011 Oct 6;152(1):116
  • Altay H, Zorlu A, Binici S, Bilgi M, Yilmaz MB, Colkesen Y, Erol T, Muderrisoglu H. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol. 2012 Jan 15;109(2):252-6
  • Sincer I, Zorlu A, Yilmaz MB, Dogan OT, Ege MR, Amioglu G, Aydin G, Ardic I, Tandogan I. Relationship between red cell distribution width and right ventricular dysfunction in patients with chronic obstructive pulmonary disease. Heart Lung. 2012 May;41(3):238-43.
  • Zorlu A, Akkaya E, Altay H, Bektasoglu G, Turkdogan KA, Sincer I, Vuruskan E, Cınar Z, Tandogan I, Yilmaz MB. The relationship between D-dimer level and the development of atrial fibrillation in patients with systolic heart failure. J Thromb Thrombolysis. 2012 May;33(4):343-8.
  • Altay H, Zorlu A, Bilgi M, Erol T, Yilmaz MB. Usefulness of parathyroid hormone as a predictor of heart failure with preserved ejection fraction. Biomarkers. 2012 May 15. [Epub ahead of print]
  • Zorlu A, Yücel H, Yontar OC, Karahan O, Tandogan I, Katrancioglu N, Yilmaz MB. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012 May 29. pii: S0066-782X2012005000048. [Epub ahead of print]
  • Ege MR, Yilmaz N, Yilmaz MB. Depression and heart failure. Int J Cardiol. 2012 Jul 26;158(3):474.
  • Ege MR, Guray U, Guray Y, Yilmaz MB, Yucel O, Zorlu A, Tandogan I. Acute heart failure with accompanying chronic obstructive pulmonary disease : Should we focus on beta blockers? Herz. 2012 Jun 16. [Epub ahead of print]
  • Beton O, Yılmaz MB, Turgut O, Tandoğan I. Association of pro-inflammatory cytokines and T-cell activation marker with CA-125 levels in obese patients with heart failure: implications for complex immunoinflammatory pathophysiology. Med Sci Monit. 2011 Aug;17(8):LE5-6.
  • Ege MR, Yılmaz N, Yılmaz MB. Depression and perceptions about heart failure predict quality of life. Heart Lung. 2011 Nov-Dec;40(6):585.
  • Ege MR, Zorlu A, Yılmaz MB. CA-125 and heart failure. Int J Cardiol. 2011 Mar 17;147(3):453-4.
  • Yontar OC, Yilmaz MB, Yalta K, Tandoğan I. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter? Anadolu Kardiyol Derg. 2010 Aug;10(4):310-6.
  • Ege MR, Yilmaz MB. Should we resynchronize all left bundle branch blocks in patients presenting with acute heart failure? Int J Cardiol. 2011 Jan 21;146(2):230.
  • Turgut O, Tandogan I, Yilmaz MB, Gul I, Zorlu A. CA125 in heart failure: implications for immunoinflammatory activity. Int J Cardiol. 2011 Jan 7;146(1):99-100.
  • Yontar OC, Yalta K, Yilmaz MB. Superiority of levosimendan over dobutamine in right ventricle failure. Crit Care Med. 2010 Jan;38(1):342-3
  • Yontar OC, Yilmaz MB, Yalta K. Levosimendan in acute and chronic right ventricle failure. Acta Anaesthesiol Scand. 2010 Jan;54(1):118-9
  • Yalta K, Yilmaz A, Turgut OO, Yilmaz MB, Karadas F, Bektasoglu G, Tandogan I. Acute heart failure and near-syncope associated with giant left atrial ball thrombus occluding left ventricular inflow tract. Eur J Echocardiogr. 2008 Jan;9(1):86-7.
  • Yilmaz A, Yalta K, Turgut OO, Yilmaz MB, Ozyol A, Kendirlioglu O, Karadas F, Tandogan I. Clinical importance of elevated CK-MB and troponin I levels in congestive heart failure. Adv Ther. 2006 Nov-Dec;23(6):1060-7.
  • Yilmaz MB, Akin Y, Biyikoglu SF, Guray U, Kisacik HL, Korkmaz S. Left ventricular thrombosis is associated with increased mean platelet volume in patients with dilated cardiomyopathy and sinus rhythm. Acta Cardiol. 2004 Feb;59(1):41-5.


Sınırlı Sorumluluk Beyanı
Web sitemizin içeriği, ziyaretçiyi bilgilendirmeye yönelik hazırlanmıştır. Sitede yer alan bilgiler, hiçbir zaman bir hekim tedavisinin ya da konsültasyonunun yerini alamaz. Bu kaynaktan yola çıkarak, ilaç tedavisine başlanması ya da mevcut tedavinin değiştirilmesi kesinlikte tavsiye edilmez. Web sitemizin içeriği, asla kişisel teşhis ya da tedavi yönteminin seçimi için değerlendirilmemelidir. Sitede kanun içeriğine aykırı ilan ve reklam yapma kastı bulunmamaktadır.© 2010 - 2018, Tüm hakları saklıdır. Gizlilik Sözleşmesi. Bu web sitesi CEOTECH tarafından yapılmıştır. Daha detaylı bilgi almak için lütfen tıklayınız.